Abstract library

12 results for "Tesselaar".
#448 Comparison of the Automated Chromogranin A Assay Using KRYPTOR Instrumentation with the Manual IRMA Assay of CisBio
Introduction: Chromogranin A (CgA) has become the most important tumor marker for neuroendocrine tumors (NET) during the last decade. To meet the need for high throughput and rapid measurements, the fully automated Thermo Scientific BRAHMS KRYPTOR CgA assay has been developed.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Catharina M Korse
#614 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors
Introduction: The diagnosis of neuroendocrine tumors (NET) is often delayed due to the vague symptoms and rareness of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Catharina M Korse
#697 Grading NET: Mitosis and Ki-67 conditio sine qua non?
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. However, as both parameters are markers for a different part of the cell cycle, their values might not lead to the same grade.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD PhD Marie-Louise Van Velthuysen
Keywords: grade, Ki-67, mitosis, NET
#1341 Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]-DOTATATE PET/CT
Introduction: Somatostatin receptor imaging with [68Ga]-DOTATATE PET/CT has become common practice in patients with NET. Current guidelines recommend discontinuing treatment with SSAs before obtaining a [68Ga]-DOTATATE PET/CT scan. The assumption is that unlabeled somatostatin may lower the detectability of lesions.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Else Aalbersberg
Keywords: DOTATATE
#1418 Extra-Pulmonary Neuroendocrine Carcinomas: A National Population Based Study
Introduction: Extra pulmonary neuroendocrine carcinomas(EPNEC) are rare tumours, this implies lack of knowledge on the burden.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MSc. Jan Maarten Van Der Zwan
Keywords: EP-NEC
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1792 Treatment and Survival of 351 Patients Diagnosed with Merkel Cell Carcinoma in 2 Melanoma and Neuroendocrine Tumor Expert-Centers in the Netherlands
Introduction: Merkel cell carcinoma (MCC) is a rare and potentially aggressive neuroendocrine carcinoma of the skin. Because of its frequency, adequate data on treatment and survival are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MSc Linde M van Veenendaal
#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs
Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Mark Kidd
#2181 Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth
Introduction: Neuroendocrine tumors (NETs) are a genetically diverse set of rare tumors, which have limited treatment options. The development of more effective therapies for NETs has been limited in part by the absence of in vitro and in vivo models that accurately represent the heterogeneity of these tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Talya Dayton
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.